Boosting Immunity against Multiple Myeloma.

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiple myeloma (MM) treatments like immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies have improved outcomes but not cured the disease.
• Novel therapies including anti-BCMA CAR-T cells, antibody-drug conjugates, and bispecific antibodies offer survival benefits but haven't eradicated all malignant cells.
• Achieving long-term complete response with minimal residual disease (MRD)-negative status remains the primary goal in multiple myeloma treatment.

Purpose of the Study:

• To review current and future immunomodulatory strategies for multiple myeloma.
• To focus on the impact of these strategies on the bone marrow (BM) immunome.
• To explore approaches targeting both myeloma cells and the BM microenvironment for sustained MRD negativity.

Main Methods:

• Literature review of current and emerging immunomodulatory therapies for multiple myeloma.
• Analysis of strategies impacting the bone marrow microenvironment.
• Focus on achieving minimal residual disease (MRD)-negative status.

Main Results:

• Current therapies improve patient outcomes but do not offer a cure for multiple myeloma.
• Novel agents show promise but have not consistently led to complete eradication of malignant cells.
• Targeting the bone marrow microenvironment is a promising strategy for sustained MRD negativity.

Conclusions:

• Sustained minimal residual disease (MRD)-negative status is crucial for prolonged survival in multiple myeloma.
• Strategies modulating the bone marrow immunome, in addition to direct anti-myeloma treatments, are essential.
• Future research should focus on combination therapies that target both myeloma cells and their supportive microenvironment.